Reader TTS

ABSTRACT BACKGROUND Benign prostatic hyperplasia, lower urinary tract symptoms, and prostate cancer often co-occur. Their effect on urinary function is an important consideration regarding

prostate cancer treatment choices. While prostate volume (PV) and urinary symptoms are commonly used in treatment choice decision making, their association with post-treatment urinary

function is unknown. We evaluated the associations between PV and baseline urinary function with treatment choice and post-treatment urinary function among men with localized prostate

cancer. METHODS We identified 1647 patients from CEASAR, a multicenter population-based, prospective cohort study of men with localized prostate cancer, for analysis. Primary outcomes were

treatment choice and health-related quality of life (HRQOL) assessed by the 26-item Expanded Prostate Index Composite (EPIC-26) at pre-specified intervals up to 5 years. Multivariable

analysis was performed, controlling for demographic and clinicopathologic features. RESULTS Median baseline PV was 36 mL (IQR 27–48), and baseline urinary irritative/obstructive domain score

was 87 (IQR 75–100). There was no observed clinically meaningful association between PV and treatment choice or post-treatment urinary function. Among patients with poor baseline urinary

function, treatment with radiation or surgery was associated with statistically and clinically significant improvement in urinary function at 6 months which was durable through 5 years

(improvement from baseline at 5 years: radiation 20.4 points, surgery 24.5 points). CONCLUSIONS PV was not found to be associated with treatment modality or post-treatment urinary

irritative/obstructive function among men treated for localized prostate cancer. Men with poor baseline urinary irritative/obstructive function improve after treatment with surgery or

radiation therapy. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 4 print issues and online access $259.00 per year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS CLINICAL SIGNIFICANCE OF PROSTATE VOLUME AND TESTOSTERONE REDUCTION ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH PROSTATE

CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY Article Open access 02 November 2022 REAL-WORLD FOUR-YEAR FUNCTIONAL AND SURGICAL OUTCOMES OF REZUM THERAPY IN YOUNGER VERSUS ELDERLY MEN

Article 24 August 2023 TWO-YEAR LONG-TERM FOLLOW-UP OF TREATMENT WITH THE OPTILUME BPH CATHETER SYSTEM IN A RANDOMIZED CONTROLLED TRIAL FOR BENIGN PROSTATIC HYPERPLASIA (THE PINNACLE STUDY)

Article Open access 29 April 2024 DATA AVAILABILITY The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

CHANGE HISTORY * _ 08 MARCH 2023 A Correction to this paper has been published: https://doi.org/10.1038/s41391-023-00658-2 _ REFERENCES * Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino

PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992;70:291–301. Article  CAS  PubMed  Google Scholar  * Sanda MG, Cadeddu JA, Kirkby E,

Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol.

2018;199:990–7. Article  PubMed  Google Scholar  * Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part

I: Introduction, Risk Assessment, Staging and Risk-Based Management. J Urol. 2022. https://doi.org/10.1097/JU.0000000000002757. * Barocas DA, Penson DF. Functional recovery following

primary treatment for prostate cancer: update from the CEASAR study. Eur Urol Focus. 2020;6:205–7. Article  PubMed  Google Scholar  * Mendenhall NP, Rausch Osian SM, Bryant CM, Hoppe BS,

Morris CG. What men want: results from a national survey on decision making for prostate cancer treatment and research participation. Clin Transl Sci. 2021; cts.13090. * Barocas DA, Chen V,

Cooperberg M, Goodman M, Graff JJ, Greenfield S, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR

study. J Comp Eff Res. 2013;2:445–60. Article  PubMed  Google Scholar  * Mandel P, Weinhold P, Michl U, Huland H, Graefen M, Tilki D. Impact of prostate volume on oncologic, perioperative,

and functional outcomes after radical prostatectomy. Prostate. 2015;75:1436–46. Article  PubMed  Google Scholar  * Ward NT, Parsons JK, Levinson AW, Bagga HS, Mettee LZ, Su L-M, et al.

Prostate size is not associated with recovery of sexual function after minimally invasive radical prostatectomy. Urology. 2011;77:952–6. Article  PubMed  Google Scholar  * Levinson AW, Bagga

HS, Pavlovich CP, Mettee LZ, Ward NT, Link RE, et al. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy. J Urol. 2008;179:1818–22.

Article  PubMed  Google Scholar  * Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument

for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245–50. Article  PubMed  Google Scholar  * Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield

TK, Litwin MS, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology. 2015;85:101–6. Article  Google Scholar  * Litwin MS, Greenfield S,

Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer. Cancer. 2007;109:1777–83. Article  PubMed  Google Scholar  *

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83. Article  Google Scholar  * Radloff LS. The

CES-D Scale. Appl Psychol Meas. 1977;1:385–401. Article  Google Scholar  * Kaplan SH, Gandek B, Greenfield S, Rogers W, Ware JE. Patient and visit characteristics related to physicians

participatory decision-making style. Med Care. 1995;33:1176–87. Article  CAS  PubMed  Google Scholar  * White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test

for heteroskedasticity. Econometrica. 1980;48:817. Article  Google Scholar  * Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Lecam L, Neyman J

(eds). Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, 1966, pp 221–34. * White IR, Royston P, Wood AM. Multiple

imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377–99. Article  PubMed  Google Scholar  * Schafer JL. Analysis of Incomplete Multivariable Data. 1st

ed. Chapman and Hall CRC Press: London, UK, 1997. * Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, et al. Does prostate size predict the development of incident

lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE Trial. Eur Urol. 2016;69:885–91. Article  PubMed  Google Scholar  * Crawford ED, Wilson SS,

McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol.

2006;175:1422–7. Article  CAS  PubMed  Google Scholar  * Vesely S, Knutson T, Damber J-E, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen,

symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37:322–8. Article  PubMed  Google Scholar  * Uberoi P, Smith CA, Lucioni A. Management of

lower urinary tract symptoms after prostate radiation. Curr Urol Rep. 2021;22:37. Article  PubMed  Google Scholar  * Masters JG, Rice ML. Improvement in urinary symptoms after radical

prostatectomy: a prospective evaluation of flow rates and symptom scores. BJU Int. 2003;91:795–7. Article  CAS  PubMed  Google Scholar  * Schwartz EJ, Lepor H. Radical retropubic

prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms. J Urol. 1999;161:1185–8. Article  CAS  PubMed  Google Scholar

  * Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl J Med.

2008;358:1250–61. Article  CAS  PubMed  Google Scholar  * Teunissen FR, Willigenburg T, Meijer RP, van Melick HHE, Verkooijen HM, van der Voort van Zyp JRN. The first patient-reported

outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating ‘trials within cohorts’ (TwiCs) for the evaluation of interventions for prostate cancer. World J Urol.

2022;40:2205–12. Article  PubMed  PubMed Central  Google Scholar  * Pepin A, Pernia M, Danner MT, Ayoob M, Yung TM, Lei S, et al. Impact of age on patient-reported outcomes following

stereotactic body radiation therapy for prostate cancer. Cureus. 2021. https://doi.org/10.7759/cureus.13780. * Wang F, Luan Y, Fan Y, Huang T, Zhu L, Lu S, et al. Comparison of the

oncological and functional outcomes of brachytherapy and radical prostatectomy for localized prostate cancer. Med (B Aires). 2022;58:1387. Google Scholar  Download references FUNDING AHRQ:

1R01HS019356, 1R01HS022640. PCORI: CE-12-11-4667. NIH/NCI: R01CA230352. NCATS/NIH: UL1TR000011. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urology, Vanderbilt University

Medical Center, Nashville, TN, USA Jacob E. Tallman, Christopher J. D. Wallis, David F. Penson & Daniel A. Barocas * Department of Biostatistics, Vanderbilt University Medical Center,

Nashville, TN, USA Zhiguo Zhao, Li-Ching Huang & Tatsuki Koyama * Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA Michael Goodman *

Department of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA Ann S. Hamilton * Department of Epidemiology, Louisiana State

University New Orleans School of Public Health, New Orleans, LA, USA Xiao-Cheng Wu * Department of Epidemiology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA Lisa E.

Paddock & Antoinette Stroup * Department of Urology, University of California, San Francisco, CA, USA Matthew R. Cooperberg * Department of Family and Preventive Medicine, University of

Utah School of Medicine, Salt Lake City, UT, USA Mia Hashibe * Department of Urology, University of Utah Health, Salt Lake City, UT, USA Brock B. O’Neil * Department of Medicine, University

of California Irvine, Irvine, CA, USA Sherrie H. Kaplan & Sheldon Greenfield * Department of Radiation Oncology, University of Texas M. D. Anderson Center, Houston, TX, USA Karen E.

Hoffman Authors * Jacob E. Tallman View author publications You can also search for this author inPubMed Google Scholar * Christopher J. D. Wallis View author publications You can also

search for this author inPubMed Google Scholar * Zhiguo Zhao View author publications You can also search for this author inPubMed Google Scholar * Li-Ching Huang View author publications

You can also search for this author inPubMed Google Scholar * David F. Penson View author publications You can also search for this author inPubMed Google Scholar * Tatsuki Koyama View

author publications You can also search for this author inPubMed Google Scholar * Michael Goodman View author publications You can also search for this author inPubMed Google Scholar * Ann

S. Hamilton View author publications You can also search for this author inPubMed Google Scholar * Xiao-Cheng Wu View author publications You can also search for this author inPubMed Google

Scholar * Lisa E. Paddock View author publications You can also search for this author inPubMed Google Scholar * Antoinette Stroup View author publications You can also search for this

author inPubMed Google Scholar * Matthew R. Cooperberg View author publications You can also search for this author inPubMed Google Scholar * Mia Hashibe View author publications You can

also search for this author inPubMed Google Scholar * Brock B. O’Neil View author publications You can also search for this author inPubMed Google Scholar * Sherrie H. Kaplan View author

publications You can also search for this author inPubMed Google Scholar * Sheldon Greenfield View author publications You can also search for this author inPubMed Google Scholar * Karen E.

Hoffman View author publications You can also search for this author inPubMed Google Scholar * Daniel A. Barocas View author publications You can also search for this author inPubMed Google

Scholar CONTRIBUTIONS JET, MD: 1,3,4,5,6. CJDW, MD, PhD, FRCSC: 1,3,4,5,6. ZZ, MS: 1,3,5,6. L-CH, PhD: 1,3,5,6. DFP, MD, MPH: 1,2,5,6. TK, PhD: 1,3,5,6. MG, MD, MPH: 1,2,5,6. ASH, PhD, MA:

1,2,5,6. X-CW, MD, MPH: 1,2,5,6. LEP, PhD, MPH: 1,2,5,6. AS, PhD: 1,2,5,6. MRC, MD, MPH: 1,2,5,6. MH, PhD:1,2,5,6. BBO’N, MD: 1,2,5,6. SHK, PhD, MS, MPH: 1,2,5,6. SG, MD: 1,2,5,6. KEH, MD,

MHSc, MPH: 1,2,5,6. DAB, MD, MPH: 1,2,3,4,5,6. (1) Conception or design of the work. (2) Data collection. (3) Data analysis and interpretation. (4) Drafting the article. (5) Critical

revision of the article. (6) Final approval of the version to be published. CORRESPONDING AUTHOR Correspondence to Jacob E. Tallman. ETHICS DECLARATIONS COMPETING INTERESTS The authors

declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In this article the statement in the Funding information section was incorrectly given as '5T32CA106183' and has been

deleted. The original article has been corrected. SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 SUPPLEMENTARY TABLE 2 SUPPLEMENTARY FIGURE 1 SUPPLEMENTARY FIGURE 2 RIGHTS AND PERMISSIONS

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author

self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Reprints and permissions ABOUT THIS ARTICLE

CITE THIS ARTICLE Tallman, J.E., Wallis, C.J.D., Zhao, Z. _et al._ Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary

function in men treated for localized prostate cancer. _Prostate Cancer Prostatic Dis_ 26, 787–794 (2023). https://doi.org/10.1038/s41391-022-00627-1 Download citation * Received: 19 October

2022 * Revised: 21 November 2022 * Accepted: 29 November 2022 * Published: 08 December 2022 * Issue Date: December 2023 * DOI: https://doi.org/10.1038/s41391-022-00627-1 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative